Syndax Pharmaceuticals Debt 2024

Syndax Pharmaceuticals Aktienanalyse

What does Syndax Pharmaceuticals do?

Syndax Pharmaceuticals Inc. is a biotechnology company based in Waltham, Massachusetts that focuses on the development of novel therapeutics for cancer and immune disorders. The company was founded in 2005 by Arlene Morris and has been listed on NASDAQ since 2014. Business model and product pipeline: Syndax develops small molecules that are capable of modulating epigenetic changes in cells. This approach is based on the understanding that cancer cells often have genetic alterations that result in changes in gene expression. By modulating such epigenetic changes, cancer cells can function normally again, which can help stop or inhibit the growth of cancer cells. The company's product pipeline includes several drugs that are being developed in various stages of clinical research. One of the most advanced programs is E2112, an orally administered drug targeting breast cancer. The drug is currently in Phase III studies that are investigating the efficacy and safety of the drug in combination with other standard therapies. Another promising program is SNDX-6352, an anti-CSF-1 receptor antibody being developed for the treatment of various types of cancer, including certain solid tumors and hematologic malignancies. The drug has been successfully tested in Phase Ib studies, and the company is currently planning to evaluate it in further clinical trials. In addition to cancer research, Syndax is also working on the development of therapeutics for various inflammatory and immunologic diseases. The company is working on a program for the treatment of idiopathic pulmonary fibrosis and also a program for the treatment of thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. In addition to internally developed drugs, the company is collaborating with other biotechnology and pharmaceutical companies to explore innovative treatment options for other diseases. The company has entered into a partnership with Japanese company Kyowa Hakko Kirin Co. Ltd. to develop and market the SNDX-6352 program. Current developments: Syndax has recently experienced strong growth and is investing significantly in research and development to expand its pipeline and expand its drugs. The company recently completed a financing round that raised $80 million to advance its development projects. A key milestone for the company was the appointment of Briggs W. Morrison as CEO in 2020. Morrison, an experienced pharmaceutical manager, was previously the Chief Executive Officer and President of Syndax until 2016. He is now returning to the company and leading efforts to develop innovative therapeutics. Morrison has previously worked at Pfizer and AstraZeneca, bringing valuable experience in the development and marketing of new drugs. Summary: Syndax Pharmaceuticals Inc. is a biotechnology company that focuses on the development of drugs for cancer and inflammatory diseases. The company has a promising product pipeline that includes several therapeutics in various stages of development, including E2112 and SNDX-6352. Syndax recently completed a strong financing round and plans to continue its research and development efforts to discover and develop new innovative therapeutics. Syndax Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Syndax Pharmaceuticals's Debt Structure

Syndax Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Syndax Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Syndax Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Syndax Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Syndax Pharmaceuticals stock

What is the debt of Syndax Pharmaceuticals this year?

Syndax Pharmaceuticals has a debt level of -295.37 USD this year.

What was the debt of Syndax Pharmaceuticals compared to the previous year?

The debt of Syndax Pharmaceuticals has increased by 297.01% compared to the previous year increased.

What are the consequences of high debt for investors in Syndax Pharmaceuticals?

High debt can pose a risk for investors of Syndax Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Syndax Pharmaceuticals?

Low debt means that Syndax Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Syndax Pharmaceuticals affect the company?

An increase in debt of Syndax Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Syndax Pharmaceuticals affect the company?

A reduction in debt of Syndax Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Syndax Pharmaceuticals?

Some factors that can influence the debt of Syndax Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Syndax Pharmaceuticals so important for investors?

The debts of Syndax Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Syndax Pharmaceuticals take to change the debt?

To change the debt, Syndax Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Syndax Pharmaceuticals pay?

Over the past 12 months, Syndax Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Syndax Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Syndax Pharmaceuticals?

The current dividend yield of Syndax Pharmaceuticals is .

When does Syndax Pharmaceuticals pay dividends?

Syndax Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Syndax Pharmaceuticals?

Syndax Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Syndax Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Syndax Pharmaceuticals located?

Syndax Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Syndax Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Syndax Pharmaceuticals from 12/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/20/2024.

When did Syndax Pharmaceuticals pay the last dividend?

The last dividend was paid out on 12/20/2024.

What was the dividend of Syndax Pharmaceuticals in the year 2023?

In the year 2023, Syndax Pharmaceuticals distributed 0 USD as dividends.

In which currency does Syndax Pharmaceuticals pay out the dividend?

The dividends of Syndax Pharmaceuticals are distributed in USD.